tas-106
Small moleculeexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jun 1, 2008 (NCT00752011)
Timeline
Indications
Mechanism of action
- tRNAINHIBITOR
tRNA inhibitor
DNA-directed RNA polymerase II subunit RPB1 inhibitor
DNA-directed RNA polymerase III subunit RPC1 inhibitor
DNA-directed RNA polymerase I subunit RPA1 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
C#C[C@@]1(O)[C@@H](CO)O[C@@H](n2ccc(N)nc2=O)[C@@H]1O- Mol. weight
- 267.24 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL573352 ↗
Also known as
- 1-(3-c-ethynyl-beta-d-ribo-pentofuranosyl)cytosine
- 1-(3-c-ethynylribopentofuranosyl)cytosine
- 3-c-ethynyl-cytidine
- 3'-ethynylcytidine
- ecyd cpd
- tas 106
- tas-106
- tas-106
- tas-106
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00737360 | Phase 2 | Aug 1, 2008 | Otsuka |
| NCT00752011 | Phase 1 | Jun 1, 2008 | Otsuka, University of Texas at Houston |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Otsuka | For profit | 2 | 1 | 2 | 2008 |
| University of Texas at Houston | Academic/Hospital | 1 | 1 | 1 | 2008 |
2 organizations
Page 1 / 1